Arcturus stock: buy or sell?
August 19th, 2019
Arcturus Therapeutics Ltd. operates as an RNA medicines company. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics.
Should I buy Arcturus stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best time to buy them. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, Arcturus stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Arcturus stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we gathered 5 ratings published for ARCT stock in the last 30 days. The general sentiment of these ratings is bullish for ARCT stock, with 5 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
Arcturus stock analysis
After boosting an exceptional 16.67% on Friday, Arcturus Therapeutics closed today at $11.07 and climbed an amazing 4.83%.
After boosting an exceptional 16.67% on Friday, Arcturus Therapeutics closed today at $11.07 and climbed an amazing 4.83%. Since last June when SMA100d and SMA200d crossed up, ARCT price gained $1.28 per share (13.07%). Since last June when ARCT stock price broke up the SMA200d line, it gained $5.29 (91.52%).
Arcturus shares climbed 4.83% this week, ending at $11.07. Early August ARCT plummed a chilling -7.84% in just one week. Late July ARCT rocketed an astounding 6.83% in just one week.
Arcturus Therapeutics stock is trading in the range of its last top and last bottom. Loosing would mean breaking the current uptrend. Breakdowns under last bottom are selling point signals for some trading strategies. By mid June, SMA20w and SMA40w crossed up triggering a rise of 74.33%. Since price and SMA40w lines crossed up late May, ARCT climbed $4.84 (77.69%).
Arcturus stock price history
Arcturus stock went public on March 1st, 2012 with a price of $6.001. Since then, ARCT stock grew a 84.50%, with a yearly average of 12.10%. If you had invested $1,000 in Arcturus stock in 2012, it would worth $845.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Arcturus stock historical price chart
ARCT stock reached 52-week highs on July/31 at $15.50, and all-time highs 2013-10-04 with a price of 188.72.
Arcturus stock price target is $17.30Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we found 4 price predictions for Arcturus Therapeutics stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-8-7||HC Wainwright||Raises Target||$16.00||$18.00||12.5%|
|2019-6-20||Chardan Capital||Set Price Target||n/a||$18.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareArcturus Therapeutics failed experts on March when it reported an Earnings per Share (EPS) of $-0.10 when the analysts' forecast was $-0.62.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual turnover report draw an astounding increase of 21.20% to $15.75 M USD. When comparing 2018 vs 2017, however, profit margin (that is, the net income divided by revenues) collapsed a -54.42% to -138.29%.
|2016||$20 M||-||$-24.60 M-120.7%||-|
|2017||$13 M||-36.23%||$-10.90 M-83.9%||-55.69%|
|2018||$16 M||21.20%||$-21.79 M-138.3%||99.83%|
Quarterly financial resultsArcturus posted $7.58 M in sales for 2018-Q4, a 121.36% up compared to previous quarter. Reported quarter earnings marked $-1.01 M with a profit margin of -13.34%. Profit margin skyrocketed a 110.90% compared to previous quarter when profit margin was -124.25%. When comparing sales to same quarter last year, Arcturus Therapeutics sales marked an exceptional gain and rocketed a 275.10%. Looking back to recent quarterly results, Arcturus posted 3 positive quarters in a row.
|2017-Q2||$4 M||-||$-1.10 M-29.2%||-|
|2017-Q3||$3 M||-12.36%||$-3.18 M-96.4%||189.08%|
|2017-Q4||$2 M||-38.71%||$-5.28 M-261.4%||66.19%|
|2018-Q2||$2 M||18.12%||$-9.95 M-417.0%||88.45%|
|2018-Q3||$3 M||43.46%||$-4.25 M-124.2%||-57.26%|
|2018-Q4||$8 M||121.36%||$-1.01 M-13.3%||-76.23%|
Arcturus ownershipWhen you are planning to buy a stock, it's always worth to overview its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Arcturus, 46.92% of all outstanding shares are owned by its staff.
In case of Arcturus Therapeutics stock, 14.51% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for ARCT stock account 0.00%, no big difference from last month.
For a better understanding, the following table shows ownership data compared to other related stocks:
|Market cap||$118.7 M||$500.6 M||$349.4 B||$122.7 B||$204.9 B|
|Total shares||10.7 M||55.1 M||2,660.0 M||1,090.0 M||2,290.0 M|
|Float shares||8.9 M||45.8 M||2,630.0 M||796.0 M||2,150.0 M|
|- Institutional holdings (%)||14.5%||78.7%||69.2%||81.5%||11.7%|
|- Insider holdings (%)||46.9%||12.4%||0.1%||0.1%||0.0%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Monday, August 19th, 2019|
|Day range||$10.21 - $11.13|
|Average true range||$1.37|
|50d mov avg||$9.66|
|100d mov avg||$8.39|
|200d mov avg||$6.89|
Arcturus performanceTo better understand Arcturus Therapeutics performance you must compare its gains with other related stocks in same sector or industry. In the following table, we compare Arcturus Therapeutics performance to Intra-Cellular Therapies, , Eli Lilly and, Novartis, Pluristem Therapeutics, Supernus Pharmaceuticals and Teva Pharmaceutical Industries:
|LLYEli Lilly and||-3.11%||-8.23%||8.71%|